Use of “big data” in drug discovery and clinical trials

• Published in: Gynecologic oncology 2016-04, Vol.141 (1), p.17-23
• Main Authors: Taglang, Guillaume, Jackson, David B
• Format: Article
• Language: English
• Subjects: Big data; Biomarkers; Clinical trials; Clinical Trials as Topic; Datasets as Topic; Drug Discovery; Hematology, Oncology and Palliative Medicine; Humans; Obstetrics and Gynecology; Precision medicine; Research Design
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2016.02.022

Abstract Oncology is undergoing a data-driven metamorphosis. Armed with new and ever more efficient molecular and information technologies, we have entered an era where data is helping us spearhead the fight against cancer. This technology driven data explosion, often referred to as “big data”, is not only expediting biomedical discovery, but it is also rapidly transforming the practice of oncology into an information science. This evolution is critical, as results to-date have revealed the immense complexity and genetic heterogeneity of patients and their tumors, a sobering reminder of the challenge facing every patient and their oncologist. This can only be addressed through development of clinico-molecular data analytics that provide a deeper understanding of the mechanisms controlling the biological and clinical response to available therapeutic options. Beyond the exciting implications for improved patient care, such advancements in predictive and evidence-based analytics stand to profoundly affect the processes of cancer drug discovery and associated clinical trials.